Rates of grade 3/4 anemia as well as RBC transfusion requirements were statistically in favor of the trilaciclib-treated group for our study, which did not reach statistical significance in the GIT28-05 study.
← all excerpts
Trilaciclib use in extensive-stage small cell lung cancer (ES-SCLC): are clinical benefits seen in the real-world setting?
1
—
—